Russian drug manufacturing is getting a shot in the arm as big pharma makes a play to become entrenched in-country. Investing in local drugmakers provides a convenient workaround to import complexities, reports MoneyControl.com.
Building and buying facilities are the chief means. Among those in on the secret: Nycomed, Novo Nordisk, AstraZeneca and Novartis, says Reuters, along with a half-dozen others are reportedly considering the idea. They are after a piece of the projected 2010 mid-double-digit percentage growth of the Russian pharma market, an appealing contrast to the global projection of 4 percent to 6 percent.
The Association of International Pharmaceutical Manufacturers in Russia expects global drugmakers to drop a combined $1 billion on setting up local production.